Stock PDSB PDS BIOTECHNOLOGY CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases PDS Biotechnology Corporation

Equities

PDSB

US70465T1079

Real-time Estimate Cboe BZX
Other stock markets
 01:04:34 2024-04-29 pm EDT 		5-day change 1st Jan Change
3.41 USD +4.28% Intraday chart for PDS Biotechnology Corporation +12.37% -32.39%
Mar. 28 B. Riley Securities Adjusts PDS Biotechnology's Price Target to $11 From $14, Maintains Buy Rating MT
Mar. 27 Empire Metals targets key milestones in Australia AN

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune HPV in Combination with KEYTRUDA in Recurrent or Metastatic Head and Neck Cancer
AQ
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
AQ
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
AQ
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
AQ
PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results
AQ
PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®
AQ
PDS Biotechnology : Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune® - Form 8-K
PU
PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer
AQ
PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference
AQ
PDS Biotechnology Reports Inducement Grant under Nasdaq Listing Rule 5635(4)
AQ
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer
AQ
PDS Biotechnology: Q3 Earnings Snapshot
AQ
PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update
AQ
PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naive Patients at 36 Months
AQ
PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 Months
AQ
PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results
AQ
PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO
AQ
PDS Biotech Announces Interim Safety and Immune Response Data from Phase Clinical trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer
AQ
PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PDSB Stock
  4. News PDS Biotechnology Corporation
  5. Press Releases